Primary source: Infographic - PRIME 5-year report highlights
Updated guidance clarifies the PRIME scheme's eligibility for medicines that address unmet medical needs and introduces revised information on early support interactions between developers and EMA.
Understanding the updated guidance is crucial for Marketing Authorisation Holders (MAHs) and sponsors to effectively engage with EMA and align their pharmacovigilance strategies during the product development lifecycle, ultimately improving patient access to new therapies.
MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.
Regulatory Intelligence Lead
As necessary, aligned with future EMA updates.
Updated guidance on the features of the PRIME scheme and release of new eligibility recommendations adopted at the CHMP meeting of July 2026. The updates likely clarify the process for seeking early support and scientific advice for high-priority medicines.
MAHs and sponsors of priority medicines should review the updated PRIME guidance to understand potential changes in early interaction expectations, particularly regarding risk management planning (RMP) and post-authorisation safety monitoring. While primarily a development-stage scheme, PRIME status leads to intensified scientific advice and accelerated assessment, requiring robust PV strategy alignment early in the product lifecycle.
MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.
The EMA revised its guidance on the PRIME scheme as of August 10, 2026. The update provides clearer expectations for developers of priority medicines regarding early support, risk management planning (RMP), and post-authorisation safety monitoring. This procedural update aims to enhance the development of drugs addressing unmet medical needs and involves intensified scientific advice and accelerated assessment processes.
What changed: Updated guidance clarifies the PRIME scheme's eligibility for medicines that address unmet medical needs and introduces revised information on early support interactions between developers and EMA.
Why it matters: Understanding the updated guidance is crucial for Marketing Authorisation Holders (MAHs) and sponsors to effectively engage with EMA and align their pharmacovigilance strategies during the product development lifecycle, ultimately improving patient access to new therapies.
Practical implication: MAHs and sponsors of priority medicines must review the updated PRIME guidance to ensure compliance with new interaction expectations, particularly regarding risk management planning and post-authorisation safety monitoring.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
